É o tipo mais comum de linfoma não-Hodgkin. Inclui os tipos mais frequentemente encontrados, que são: linfoma difuso de grandes células B, linfoma folicular, linfoma linfocítico de pequenas células e linfoma de células B da zona marginal. -- 2003
Introdução
O que você precisa saber de cara
O **linfoma não-Hodgkin de células B** é o grupo mais frequente entre os linfomas não-Hodgkin, reunindo diferentes subtipos celulares como o folicular e o difuso de grandes células B. A pessoa acometida pode manifestar sinais variados, incluindo **edema pedal** (inchaço nos pés), **palidez**, **vertigem** e tendência a ter **infecções recorrentes**. Internacionalmente, existem medicamentos aprovados como o **cloridrato de bendamustina**, mas a doença não consta na lista de PCDTs de doenças raras do Ministério da Saúde e não tem medicamentos dispensados pelo SUS cadastrados neste registro. Além disso, a CONITEC avaliou e recusou formalmente a incorporação do rituximabe subcutâneo pela Portaria SCTIE/MS nº 18/2018.
É o tipo mais comum de linfoma não-Hodgkin. Inclui os tipos mais frequentemente encontrados, que são: linfoma difuso de grandes células B, linfoma folicular, linfoma linfocítico de pequenas células e linfoma de células B da zona marginal. -- 2003
Tem tratamento?
Escala de raridade
<1/50kMuito rara
1/20kRara
1/10kPouco freq.
1/5kIncomum
1/2k
Encontrou um erro ou informação desatualizada? Sugira uma correção →
Entender a doença
Do básico ao detalhe, leia no seu ritmo
Preparando trilha educativa...
Sinais e sintomas
O que aparece no corpo e com que frequência cada sintoma acontece
Partes do corpo afetadas
+ 34 sintomas em outras categorias
Características mais comuns
Os sintomas variam de pessoa para pessoa. Abaixo estão as 89 características clínicas mais associadas, ordenadas por frequência.
Linha do tempo da pesquisa
Encontrou um erro ou informação desatualizada? Sugira uma correção →
Genética e causas
O que está alterado no DNA e como passa nas famílias
Genes associados
29 genes identificados com associação a esta condição.
Immunodeficiency 68
An autosomal recessive primary immunodeficiency characterized by life-threatening, often recurrent, pyogenic bacterial infections, including invasive pneumococcal disease, beginning in infancy or early childhood.
Immunodeficiency 12
A primary immunodeficiency characterized by onset in infancy of recurrent bacterial and candidal infections resulting in bronchiectasis and growth delay. Manifestations include mastoiditis, aphthous ulcers, cheilitis, gingivitis, esophagitis, gastritis, duodenitis, and meningitis. Levels of absolute lymphocytes and serum immunoglobulins are normal, but specific antibody titers are low despite immunization, and T-cells show impaired proliferative responses to mitogens.
Leukemia, chronic lymphocytic
A chronic leukemia in which functionally incompetent B-lymphocytes progressively accumulate in the bone marrow, blood, and lymphoid tissues. The clinical evolution of the disorder is heterogeneous, with some patients having indolent disease and others having aggressive disease and short survival.
Immunodeficiency 84
An autosomal recessive immunologic disorder characterized by recurrent sinopulmonary infections from childhood associated with low levels of B cells and impaired early B-cell development. There may also be variable T-cell abnormalities. Patients have increased susceptibility to infection with Epstein-Barr virus and a propensity for the development of lymphoma in adulthood.
Congenital anomalies of kidney and urinary tract syndrome with or without hearing loss, abnormal ears, or developmental delay
An autosomal dominant disorder characterized by variable congenital anomalies of the kidney and urinary tract, sometimes resulting in renal dysfunction or failure, dysmorphic facial features, and abnormalities of the outer ear. Most patients have hearing loss, and some may have global developmental delay.
Intellectual developmental disorder, autosomal dominant 26
A disorder characterized by significantly below average general intellectual functioning associated with impairments in adaptive behavior and manifested during the developmental period. Additional MRD26 features include autism, short stature, microcephaly, cerebral palsy, and facial dysmorphisms.
Multiple myeloma
A malignant tumor of plasma cells usually arising in the bone marrow and characterized by diffuse involvement of the skeletal system, hyperglobulinemia, Bence-Jones proteinuria and anemia. Complications of multiple myeloma are bone pain, hypercalcemia, renal failure and spinal cord compression. The aberrant antibodies that are produced lead to impaired humoral immunity and patients have a high prevalence of infection. Amyloidosis may develop in some patients. Multiple myeloma is part of a spectrum of diseases ranging from monoclonal gammopathy of unknown significance (MGUS) to plasma cell leukemia.
Tumor predisposition syndrome 3
An autosomal dominant disorder characterized by an increased risk for the development of various types of benign and malignant neoplasms throughout life, with age-dependent penetrance. Affected individuals can develop neoplasms involving epithelial, mesenchymal, and neuronal tissues, as well as lymphoid and myeloid cancers. The disorder is associated with elongated telomeres.
Ataxia telangiectasia
A rare recessive disorder characterized by progressive cerebellar ataxia, dilation of the blood vessels in the conjunctiva and eyeballs, immunodeficiency, growth retardation and sexual immaturity. Patients have a strong predisposition to cancer; about 30% of patients develop tumors, particularly lymphomas and leukemias. Cells from affected individuals are highly sensitive to damage by ionizing radiation and resistant to inhibition of DNA synthesis following irradiation.
Medicamentos aprovados (FDA)
1 medicamento encontrado nos registros da FDA americana.
Variantes genéticas (ClinVar)
139 variantes patogênicas registradas no ClinVar.
Classificação de variantes (ClinVar)
Distribuição de 1 variantes classificadas pelo ClinVar.
Vias biológicas (Reactome)
247 vias biológicas associadas aos genes desta condição.
Diagnóstico
Os sinais que médicos procuram e os exames que confirmam
Tratamento e manejo
Remédios, cuidados de apoio e o que precisa acompanhar
Onde tratar no SUS
Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)
🇧🇷 Atendimento SUS — Linfoma não-Hodgkin de células B
Selecione um estado ou use sua localização para ver resultados.
Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.
Pesquisa ativa
Ensaios clínicos abertos e novidades científicas recentes
Ensaios em destaque
Com ensaio aberto em 27 países. O ponto verde marca onde há vaga agora.
🟢 Recrutando agora
77 pesquisas recrutando participantes. Converse com seu médico sobre a possibilidade de participar.
Outros ensaios clínicos
237 ensaios clínicos encontrados, 132 ativos.
Publicações mais relevantes
Mostrando amostra de 200 publicações de um total de 1.309
Molecular Features of Response and Resistance to Glofitamab, a T-Cell Engager for treatment of Large B-Cell Lymphoma.
T-Cell Engagers (TCEs) have recently transformed the therapeutic landscape of hematological malignancies, including relapsed or refractory B-cell non-Hodgkin lymphoma (R/R B-NHL). However, the variability in patient responses underscores the need for a deeper mechanistic understanding of the factors driving efficacy. Immune cell composition and T-cell functional states are emerging as critical determinants of immunotherapy outcomes. Recent advances in scRNA-seq technologies have enabled high-resolution characterization of T-cell states, revealing a spectrum from highly activated effectors to exhausted or dysfunctional subsets within the tumor microenvironment (TME). In this study, we conducted longitudinal scRNA-seq analyses and functional assessments of peripheral blood immune cells (PBMC) from glofitamab-treated R/R B-NHL patients, achieving complete metabolic responders (CMR) or progressive metabolic disease (PMD). Our findings reveal that the maintenance of naive-like ("fresher") T-cell states (particularly the fresher cytotoxic T cells) at early timepoints is associated with clinical efficacy. In line with molecular data, T cells from responders exhibited enhanced functional activity compared to non-responders. Furthermore, the analysis of patient PBMCs and intra-tumor T cells from preclinical tumor models after consecutive glofitamab treatments revealed sustained functional activity, underscoring the long-term durability of T-cell responses. Combination of glofitamab with 4-1BB co-stimulation translated into increased proportions of intra-tumor T cells having a "fresher", naive-like phenotype, ultimately leading to stronger anti-tumor efficacy. Taken together, our findings underscore the therapeutic relevance of "fresher" naive-like T-cell states and the potential of leveraging 4-1BB co-stimulation to overcome TCE resistance and improve clinical responses in aggressive lymphomas.
Tafasitamab as Monotherapy or in Combination in Japanese Patients With B-Cell Non-Hodgkin Lymphoma: Results From the Phase 1b J-MIND Study.
We conducted a phase 1b study evaluating safety and tolerability of tafasitamab, a CD19-targeting immunotherapy, in Japanese patients with B-cell non-Hodgkin lymphoma (NHL). Eligible patients were ≥ 18 years old with relapsed/refractory (R/R) B-cell NHL (Group 1), R/R diffuse large B-cell lymphoma (DLBCL; Groups 3 and 4), or untreated DLBCL (Group 5). Patients received tafasitamab starting at 12 mg/kg qw (Group 1, n = 6), tafasitamab + lenalidomide starting at 25 mg qd for ≤ 12 cycles (Group 3, n = 6), tafasitamab + parsaclisib starting at 20 mg qd (Days 1-56) then 2.5 mg qd (Group 4, n = 6), or tafasitamab + lenalidomide combined with R-CHOP for ≤ 6 cycles (Group 5, n = 6). Primary objective was safety and tolerability of tafasitamab alone and in combination; exploratory objectives included efficacy. At data cutoff (August 31, 2023), 24 patients were treated. All patients experienced treatment-emergent adverse events (TEAEs). Two patients experienced a dose-limiting toxicity; liver disorder (grade 4) considered related to lenalidomide (Group 3, n = 1), and febrile neutropenia (grade 3) considered related to lenalidomide and R-CHOP (Group 5, n = 1). Most common TEAEs across groups were hematological and included neutropenia, leukopenia, thrombocytopenia, and anemia; most common non-hematological TEAEs included increased alanine aminotransferase, increased aspartate aminotransferase, diarrhea, nausea, constipation, and infusion-related reactions. No serious tafasitamab treatment-related or fatal TEAEs were observed. Results suggest tafasitamab alone or in combination demonstrates a manageable safety profile in Japanese patients with B-cell NHL. Preliminary efficacy results from the study are reported. However, results should be interpreted with caution due to the small sample size, with further studies warranted to confirm these findings. Trial Registration: NCT04661007; jRCT2031200357.
Allogeneic HCT as consolidation in B-cell lymphomas after exposure to bispecific antibodies: a GETH-TC study.
Bispecific antibodies (BsAb) targeting CD20 and CD3 have shown efficacy for relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL), but their impact on outcomes following allogeneic hematopoietic cell transplantation (alloHCT) remains unclear. In this international, retrospective study, we compared outcomes of adult patients with R/R B-NHL undergoing first alloHCT after BsAb exposure (n = 47) versus a historical BsAb-naïve cohort (n = 101). Baseline imbalances were addressed using inverse probability of treatment weighting (IPTW) and propensity score matching (PSM). The primary end point was nonrelapse mortality (NRM); secondary end points included overall survival (OS), progression-free survival (PFS), cumulative incidence of relapse (CIR), graft-versus-host disease (GVHD), engraftment, and GVHD/relapse-free survival (GRFS). In the overall cohort, 2-year NRM did not differ significantly between BsAb-exposed and BsAb-naïve groups (IPTW: 29.1% vs 31.4%, P = 0.80; PSM: 35.8% vs. 27.9%, P = 0.43). CIR was significantly lower in BsAb-exposed patients after IPTW (7.4% vs 20.0%, P = 0.01), but not in PSM (9.5% vs 23.4%, P = 0.06). OS, GVHD, GRFS, and engraftment were comparable. In a prespecified subanalysis limited to large B-cell lymphomas, CIR differences were consistent across IPTW (6.1% vs 21.1%, P = 0.01) and PSM (9.2% vs 33.3%, P = 0.03), reinforcing a potential benefit of prior BsAb therapy. A significant improvement in PFS was observed in this subgroup with IPTW (55.5% vs 36.6%; P = 0.04), but not in PSM (P = 0.20). Prior BsAb exposure does not adversely impact alloHCT safety and may be associated with improved disease control. Prospective studies are warranted to define optimal sequencing in this high-risk population.
Zamtocabtagene Autoleucel in Relapsed/refractory B-NHL: 5-year Follow Up of a CD20/19 tandem CAR T Cell Phase 1 Trial.
Emerging long-term data indicates relapse rates of over 50% after CD19 redirected chimeric antigen receptor (CAR) T cell therapy in relapsed or refractory (r/r) B-cell non-Hodgkin lymphoma (B-NHL). To reduce selective pressure on the CD19 antigen we conducted a first-in-human phase I clinical trial of zamtocabtagene autoleucel (zamto-cel) - a non-cryopreserved tandem CD20-CD19-directed CAR-T cell therapy. Two predefined dose levels (DL1=1x106 and DL2=2.5x106 CAR+ T cells/kg body) were applied. The primary endpoint (EP) was the maximum tolerated dose (MTD). Secondary EPs included adverse events (AEs), best overall response (BOR) and biomarker assessments. A total of 12 patients, 6 per dose level were treated. No DLT and no cytokine release syndrome (CRS) or immune effector cell-associated neurotoxicity syndrome (ICANS) grade ≥3 were observed. Thus, MTD was not reached. The BOR by investigator assessment was 75% with 5/12 patients (42%) achieving complete remission (CR) until month 12 with no relapse in clinical evaluation up to 5 years after infusion. CR was associated with higher mean Cmax and detection of zamto-cel beyond month 6. Additional product characterization revealed increased expression of CD27 and CD127 along with increased expansion of CAR+ TCM cells in patients with CR, thus facilitating persistence and improved outcomes in r/r B-NHL treated with zamto-cel. Based on the promising risk-to-benefit ratio, evaluation of zamto-cel at DL2 is ongoing in pivotal Phase II clinical trials for patients with r/r aggressive B-NHL. This trial was registered at www.clinicaltrials.gov as #NCT03870945.
Implementation Science Methodology for the Successful Introduction of High-Dose Methotrexate for the Treatment of Pediatric Mature B-Cell Non-Hodgkin Lymphoma in a Resource-Limited Setting.
Despite the excellent outcomes achieved for pediatric mature B-cell non-Hodgkin lymphoma (MB-NHL) in high-income countries, outcomes remain very poor in low- and middle-income countries. High-dose methotrexate (HD-MTX), which is highly efficacious for the disease, is still not commonly used in low-resource settings due to the potential for treatment-associated toxicity. Though there have been more recent reports of successful use of HD-MTX in resource-limited settings, there are no reports to date regarding the methodology used to safely introduce HD-MTX in these environments. Subsequently, at our treatment center in northern Tanzania, we endeavored to utilize implementation science methodology to elucidate generalizable methods to allow for a safe introduction of HD-MTX in a resource-limited setting. The Active Implementation Frameworks were utilized as a starting point to generate an initial implementation plan. Intervention fit was assessed, and resource mapping and cost analysis were completed. Key stakeholders were identified and engaged. Novel educational strategies, decision support tools, and protocol fidelity monitoring systems were developed. Following completion of all planning and education activities, use of a new HD-MTX containing MB-NHL protocol began in October of 2024. As of June 2025, 27 cycles of HD-MTX have been given to a cumulative total of 10 patients. Few protocol deviations have occurred, and only one Grade III non-hematologic adverse event has been reported. The use of implementation science methodology allowed a careful introduction of the use of HD-MTX for the treatment of pediatric MB-NHL in a resource-limited setting.
Publicações recentes
Diffuse Gastrointestinal Polyposis Revealing Mantle Cell Lymphoma: A Case Highlighting a Diagnostic Pitfall.
Isolated levator palpebrae superioris enlargement as the sole harbinger of primary orbital lymphoma.
Advanced Mature B-Cell Non-Hodgkin Lymphoma: Rituximab Works; However, Supportive Care Remains the Real Challenge.
Minimal residual disease guided treatment approaches in non-Hodgkin lymphoma-Where we are and where we're headed.
Polatuzumab vedotin and obinutuzumab combination in octogenarians with B-cell non-Hodgkin lymphoma.
📚 EuropePMC732 artigos no totalmostrando 199
Zanubrutinib in AL Amyloidosis Associated With Waldenström Macroglobulinemia and Other B-Cell Non-Hodgkin Lymphoma.
American journal of hematologyComparative pathogenesis and management of orbital/conjunctival and gastric MALT lymphoma: Microbial drivers, molecular mechanisms, and therapeutic implications.
Survey of ophthalmologyIncidence of severe COVID-19 in patients with chronic lymphocytic leukaemia or indolent B-cell non-Hodgkin lymphoma who received vaccination and pre-exposure prophylaxis with tixagevimab and cilgavimab in Italy: An observational study by the GIMEMA working party on chronic lymphoproliferative disorders and by the Fondazione Italiana Linfomi.
British journal of haematologyBispecific antibodies followed by allogeneic hematopoietic stem cell transplantation as rescue therapy in refractory/relapsed B cell non-Hodgkin lymphoma: a real-life experience.
Bone marrow transplantationLow-grade B-cell non-Hodgkin lymphoma in the sternocleidomastoid muscle: a case report and review of literature.
Frontiers in oncologyPreliminary evaluation of Chidamide in combination with novel [177Lu]Lu-DOTAGA-rituximab in rituximab-resistant Raji cells.
Cancer treatment and research communicationsCase Report: Glofitamab in the treatment of a patient with central nervous system-involved Burkitt lymphoma.
Frontiers in oncologyCharacterization of JNJ-80948543 a novel CD79bxCD20xCD3 trispecific antibody for B-cell non-Hodgkin lymphoma.
HaematologicaClinical characteristics, treatment patterns, and survival in mantle cell lymphoma: a real-world cohort.
Frontiers in oncologyLong-term follow-up demonstrates the curative potential of dual CD19/CD22 CAR-T-cell therapy alone or combined with autologous stem cell transplantation in TP53-altered relapsed/refractory B-cell non-Hodgkin lymphoma.
Signal transduction and targeted therapyDiscovery of BMS-986458, a Potent and Selective B-Cell Lymphoma 6 Protein Ligand-Directed Degrader, for the Treatment of B-Cell Non-Hodgkin Lymphoma.
Journal of medicinal chemistryGuided by target selection, inotuzumab ozogamicin successfully salvaged a patient with refractory follicular lymphoma after anti-CD19 and anti-CD22 CAR T-cell therapy: a case report and literature review.
Annals of hematologyMalignant B cells expressing SIRPα are highly proliferative and are associated with inferior clinical outcomes in B-cell non-Hodgkin lymphoma.
LeukemiaTargeted panel sequencing for refining B-cell lymphoma diagnosis: a real-life, reference center experience.
Virchows Archiv : an international journal of pathologyPrimary breast lymphoma: Case report and literature review.
Radiology case reportsRecurrent Urinary Tract Infections in a Patient with Diffuse Large B-Cell Lymphoma and Severe COVID-19: A Single Case of Suspected Immunosuppression Where Antibacterial Therapy Was Not Enough.
Antibiotics (Basel, Switzerland)A proimmunotoxin nanodrug targeting AIDS-associated non-Hodgkin lymphoma.
Journal of controlled release : official journal of the Controlled Release SocietyMantle Cell Lymphoma Mimicking Parotid Neoplasm: A Rare Case Report.
Iranian journal of otorhinolaryngologyLong-term survival and successful pregnancy in a Nigerian woman with concurrent diagnosis of non-Hodgkin lymphoma and chronic myeloid leukemia: a case report.
Journal of medical case reportsMolecular Features of Response and Resistance to Glofitamab, a T-Cell Engager for treatment of Large B-Cell Lymphoma.
Blood advancesTafasitamab as Monotherapy or in Combination in Japanese Patients With B-Cell Non-Hodgkin Lymphoma: Results From the Phase 1b J-MIND Study.
Cancer scienceDiagnostic challenges in Burkitt's lymphoma with skull base and paravertebral involvement, and hearing loss: a case report.
Journal of medical case reportsTP53 mutation heterogeneity reveals distinct prognoses in mantle cell lymphoma.
Annals of hematologyLow T3 syndrome in children with aggressive mature B-cell non-Hodgkin lymphoma.
International journal of cancerAllogeneic HCT as consolidation in B-cell lymphomas after exposure to bispecific antibodies: a GETH-TC study.
Blood advancesGlycolysis-Driven Immune Subtypes in the Tumor Microenvironment Determine Clinical Outcomes in Diffuse Large B-Cell Lymphoma.
CancersZamtocabtagene Autoleucel in Relapsed/refractory B-NHL: 5-year Follow Up of a CD20/19 tandem CAR T Cell Phase 1 Trial.
Blood advancesTrends in Incidence and Survival of Patients With Primary Effusion Lymphoma in the United States: A Population Based Cohort Study.
Hematological oncologyBurkitt Lymphoma Presenting as Acute Abdomen: Beyond Infection and Diverticulitis.
CureusImplementation Science Methodology for the Successful Introduction of High-Dose Methotrexate for the Treatment of Pediatric Mature B-Cell Non-Hodgkin Lymphoma in a Resource-Limited Setting.
Pediatric blood & cancerClonal Hematopoiesis and Lymphoma-Associated Mutations in Hematopoietic Progenitors in B-Cell Non-Hodgkin Lymphoma.
BloodAppendiceal Intussusception Secondary to Mantle Cell Lymphoma: A Report of a Rare Case.
Cureus[Pediatric burkitt lymphoma primarily involving the adenoids: a case report and literature review].
Lin chuang er bi yan hou tou jing wai ke za zhi = Journal of clinical otorhinolaryngology head and neck surgeryBreast Mass as an Atypical Presentation of Non-Hodgkin Lymphoma.
CureusCAR-T for all? Barriers, facilitators, and interventions to commercial CAR T-cell therapy access.
Blood reviews[Expert consensus on the management practice of CD19 CAR-T cell therapy for B-cell lymphoma in China (2025 edition)].
Zhonghua zhong liu za zhi [Chinese journal of oncology]Efficacy and Safety of Capivasertib (AZD5363), a Potent, Oral Pan-AKT Inhibitor, in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (CAPITAL).
Clinical cancer research : an official journal of the American Association for Cancer ResearchUnderstanding Hodgkin and B-Cell Non-Hodgkin Lymphoma Progression in Patients Awaiting Autologous Transplant in a Resource-Constrained Setting.
Transplantation and cellular therapyIn the diffuse large B-cell lymphoma microenvironment, autophagy genes are upregulated in pro-inflammatory macrophages and linked to BCL2 overexpression.
Frontiers in immunologyMultiple skin tumors in a patient treated with orelabrutinib for mantle-cell lymphoma: Case report.
Medicine[Endotracheal mantle cell lymphoma: a case report].
Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseasesA high-throughput bone marrow 3D co-culture system to study resistance to BCR signalling targeted agents in B-NHL.
British journal of haematologyPharmacokinetics of Odronextamab, A Bispecific T-Cell-Engaging Antibody, in Adult Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma.
CPT: pharmacometrics & systems pharmacologyEmerging immunotherapy advances for non-Hodgkin lymphomas: engaging T cells in the fight.
Hematology. American Society of Hematology. Education ProgramTerminal ileum Burkitt's lymphoma related ileocolic intussusception in a five-year-old child: a case report and review of literature.
International journal of surgery case reportsPrimary B-cell non-Hodgkin lymphoma of the larynx in children: report of two cases and a review of the literature.
The Turkish journal of pediatricsA Single Colonic Polyp Having Both Tubular Adenoma and Mantle Cell Lymphoma: A Case Report.
Case reports in gastroenterologyPrognostic implication of serum levels of IL-6 and IL-10 in children and adolescents with aggressive mature B-cell non-Hodgkin lymphoma.
BMC cancerClinical and molecular variations in Burkitt lymphoma.
Translational oncologyMantle cell lymphoma presenting primarily as cutaneous lesions: A case report.
World journal of clinical casesAll That Glitters Is Not Gold: Crystal-Storing Histiocytosis Presenting as a Lung Mass.
International journal of surgical pathologyEpidemiology and management of malignancies in patients with inborn errors of immunity-An ESID registry study of 19,959 patients.
The Journal of allergy and clinical immunologyCRS or ICANS Are Rare Beyond 2 Weeks After Lisocabtagene Maraleucel Infusion: Data From Clinical Trials and the Real-World Setting.
Transplantation and cellular therapyAppendiceal B-cell non-Hodgkin lymphoma presenting as recurrent appendicitis.
BMJ case reportsMandibular Follicular Lymphoma: A Rare Extranodal Presentation With Initial Facial Bone Involvement.
CureusA phase 1 study of blinatumomab/lenalidomide in relapsed/refractory B-cell lymphoma: toxicity, efficacy, and correlative analysis.
Blood advancesEfficacy and safety of radiotherapy as a bridging strategy to CD19-targeted CAR-T therapy: systematic review and meta-analysis.
Leukemia & lymphomaPrimary Splenic Follicular Lymphoma Presenting As Isolated Splenomegaly: A Case Report.
CureusThe Relationship Between IL-6 and IL-10 Expression Levels and the Prognosis in B-Cell Non-Hodgkin Lymphoma Patients Treated with R-CHOP.
Journal of inflammation researchA narrative review on the lactic acidosis and hypoglycemia in burkitt lymphoma: navigating metabolic changes.
Annals of medicine and surgery (2012)B7-H7 knockdown suppresses the proliferation, metastasis, and drug resistance of B-cell non-Hodgkin lymphoma cells by inhibiting the PI3K/Akt pathway.
Frontiers in oncologyComprehensive investigation of cuproptosis-related genes in clinical features, biological characteristics, and immune microenvironment in B-cell Non-Hodgkin lymphoma.
Journal of translational internal medicineA Rare Combination: Cold Agglutinin Disease Followed by Waldenström Macroglobulinemia-A Case of Early Treatment Response.
Diagnostics (Basel, Switzerland)[Bendamustine combined with anti-CD20 monoclonal antibody in the first-line treatment of older patients with indolent B-cell non-Hodgkin lymphoma: a multicenter retrospective study].
Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhiThe emerging role of tafasitamab in follicular lymphoma.
Leukemia & lymphomaVertebral Involvement in Pediatric Burkitt Lymphoma: A Case Report.
CureusMODELING DRUG-ORGAN INTERACTIONS AND OPTIMIZING IMMUNOTHERAPY: A QUANTITATIVE SYSTEMS PHARMACOLOGY AND ODRONEXTAMAB DYNAMICS.
Georgian medical news"B" symptoms and CBV conditioning negatively impact survival in mantle cell lymphoma patients undergoing autologous stem cell transplantation.
Annals of hematologyVital ileoscopy: a step beyond colonoscopy in positive fecal occult blood test.
Revista espanola de enfermedades digestivasMantle cell lymphoma with hypereosinophilia: A case report.
TumoriAssessment of Treatment Response in Patients With Diffuse Large B-cell Non-Hodgkin Lymphoma Using the Deauville Criteria: A Case Report and Literature Review.
CureusBurkitt Lymphoma: An Atypical Presentation and Dismal Outcome.
CureusBruton Tyrosine Kinase Inhibitors in Mantle Cell Lymphoma: What Are the Current Options?
European journal of haematologyOvercoming barriers to referral for CAR T-cell therapy in patients with non-Hodgkin aggressive B-cell lymphomas: A Delphi consensus.
CytotherapyIsolated Thrombocytopenia as the Initial and Sole Manifestation of Bone Marrow B-Cell Lymphoma in an Elderly Female.
European journal of case reports in internal medicineCD27 Agonist Antibodies Mediate Clinical Responses through Intratumoral Stimulation in B-cell Malignancies: Multicenter RiVa Trial.
Clinical cancer research : an official journal of the American Association for Cancer ResearchSuccessful Treatment of Diffuse Large B-Cell Lymphoma and Antisynthetase Syndrome with Bispecific Antibody Glofitamab.
Cancer management and researchSplenic marginal zone lymphoma associated with chronic inflammatory demyelinating polyradiculoneuropathy: a case report.
Journal of medicine and lifeEuropean-based polygenic risk score and genome-wide association study of B-cell non-Hodgkin lymphoma subtypes in Israeli Jews and Palestinian Arabs.
British journal of haematologyUSF1-induced RPS6KB2 activation influences aggressive phenotype in B-cell non-Hodgkin lymphoma.
Human cellThe MCL elderly III trial protocol: an international, randomized, open-label phase II trial to investigate the combinations of venetoclax, ibrutinib and rituximab or bendamustine, ibrutinib and rituximab in patients with treatment naive mantle cell lymphoma not eligible for dose-intensive treatment.
BMC cancerGlycan shielding enables TCR-sufficient allogeneic CAR-T therapy.
CellSOX11 modulates BCR signaling through the PAX5/CD19 axis for therapeutic targeting in BTK-resistant mantle cell lymphoma.
Blood advancesManagement of Adverse Reactions to Loncastuximab in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
Hematological oncologySafety and efficacy of autologous humanized CD19 CAR-T cell therapy for relapsed/refractory B-cell non-Hodgkin lymphoma.
Bone marrow transplantationMesenteric Mass Causing Bowel Obstruction in Waldenström Macroglobulinemia.
CureusInfectious Complications in Patients with B-Cell Non-Hodgkin Lymphoma Treated with Bispecific Antibodies.
CancersOrbital atypical lymphocytic panniculitis preceding conjunctival marginal zone lymphoma in the same patient with undifferentiated connective tissue disease: a case-based review.
Rheumatology internationalIdentifying high-risk patients with MALT lymphoma undergoing first-line therapy for disease progression.
Expert review of hematologyTreatment outcomes and survival analysis of pediatric mature B-Cell non-Hodgkin lymphoma: A retrospective study comparing LMB96 and R-CHOP regimens.
Leukemia research reportsComplicated appendicitis as a rare presentation of Burkitt's lymphoma: a case report.
Journal of surgical case reportsPrimary Colorectal Lymphoma Presenting as a Perisigmoid Abscess: A Report of a Rare Case.
CureusSodium 2-Mercaptoethanesulfonate (MESNA), Ifosfamide, Mitoxantrone, and Etoposide (MINE) in Transplant-Ineligible Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Is the Old Regimen Still Gold?
CureusClinicopathological and neuroradiological presentation in an immuno-deficiency patient with central nervous system recurrence of Burkitt lymphoma: an extremely rare case with complete remission achieved twice after GMALL-B-ALL/NHL2002 and R-MIV protocols.
Folia neuropathologicaPrevention and management of infectious diseases in pregnant women with haematological malignancies.
The Lancet. HaematologyLiquid-liquid phase separation of ZHX2 protects DLBCL cells against ferroptosis through induction of SLC3A2.
LeukemiaA Phase I Trial of Evorpacept, Lenalidomide, and Rituximab for Patients with B-Cell Non-Hodgkin Lymphoma.
Clinical cancer research : an official journal of the American Association for Cancer ResearchA Hyperacute Presentation of Small Cell, Non-Nodal Mantle Cell Lymphoma.
Case reports in hematologyEfficacy and safety of rituximab-based chemoimmunotherapy in adult patients with Burkitt lymphoma in Korea.
Frontiers in oncologyGermline mutations in B-cell non-Hodgkin lymphoma-associated hemophagocytic lymphohistiocytosis (LA-HLH) and patient outcomes.
Seminars in oncologySurvival after anti-CD19 CAR T-cell therapy for B-cell non-Hodgkin lymphoma and CLL with 10 years of follow-up.
Blood advancesUnexplained Bilateral Adrenal Hemorrhage and Adrenal Insufficiency Unveiling Burkitt's Lymphoma.
AACE endocrinology and diabetesLong-acting lipegfilgrastim and antimicrobials as vigorous primary prophylaxis in bendamustine-treated patients with indolent B cell non-Hodgkin lymphoma: a multicentric real-life experience.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in CancerChimeric antigen receptor T-cell therapy in aggressive lymphomas.
Current opinion in oncologyNodal Marginal Zone Lymphoma with Simultaneous Transformation at Diagnosis and Pleural Effusion as the Initial Presentation: A Case Report.
Acta medica Lituanica[Clinical study on intravenous human immunoglobulin (pH4) for hypogammaglobulinemia and infection risk following CD20 monoclonal antibody therapy in patients with B-cell non-Hodgkin lymphoma].
Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhiFacts and Hopes: CAR T-Cell Therapy and Immune Contexture in Non-Hodgkin Lymphoma.
Clinical cancer research : an official journal of the American Association for Cancer ResearchThe evolving treatment paradigm of chimeric antigen receptor T-cell therapy in lymphoma.
Current opinion in oncologyTargeting CD30L in B-cell non-Hodgkin lymphoma: novel peptide conjugates and their therapeutic potential.
Molecular cancerCirculating Tumor DNA in Pediatric Mature B-Cell Non-Hodgkin Lymphoma for Genotyping and Minimal Disease Monitoring.
Pediatric blood & cancerPulmonary MALT lymphoma diagnosed with transbronchial lung cryobiopsy after unsuccessful transbronchial lung biopsy: a case report.
Frontiers in medicinePD-L1 Expression and Tumor Microenvironment Dynamics in Diffuse Large B-Cell Lymphoma: Immunophenotypic Insights.
Journal of medicine and lifeComparative infection risk in CAR T vs bispecific antibodies in B-cell lymphoma: a systematic review and meta-analysis.
Blood advancesReal-World Treatment Patterns and Out-of-Pocket Costs After CAR T-Cell Therapy in Commercially Insured Patients With B-Cell Non-Hodgkin Lymphoma in the United States.
Transplantation and cellular therapyResistance Mechanism for Zanubrutinib in Marginal Zone Lymphoma.
Journal of the National Comprehensive Cancer Network : JNCCNSevere Hypercalcemia in Burkitt Lymphoma Following Heart Transplant in an Elderly Male.
CureusNovel PI3Kδ inhibitor exerts antitumor activity in Burkitt lymphoma by inducing ROS-dependent apoptosis.
Medical oncology (Northwood, London, England)Long-Term Outcomes After Allogeneic Hematopoietic Stem Cell Transplantation in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma: An Italian Multicenter Collaborative Study.
Transplantation and cellular therapyCombinability of epcoritamab CD20-targeting T-cell engager and CD20 antibody-targeted therapies in B-cell non-Hodgkin lymphoma.
Leukemia & lymphomaNodular Lymphocyte-Predominant Hodgkin Lymphoma: Update on Biology and Treatment.
Hematological oncologyIGH/IGK gene rearrangement in the diagnosis of B-cell non-Hodgkin lymphoma: experience from three centers.
Annals of hematology[Modern systemic treatment-bispecific antibodies and CAR-T cell therapy : Clinical management, mechanisms of action, outcomes].
Radiologie (Heidelberg, Germany)Comparison of the safety profiles of CD19-targeting CAR T-cell therapy in patients with SLE and B-cell lymphoma.
BloodDiagnosis and treatment of metachronous multiple primary carcinoma: A case report and review of literature.
World journal of clinical oncologyA rare case of co-occurrence of lupus nephritis and lymphoma.
Indian journal of pathology & microbiologyMalignancies after Chimeric Antigen Receptor T Cell Therapy.
Transplantation and cellular therapyEfficacy and safety of a novel CD19, CD22 dual-targeted fully human loop bi-CAR-T for the treatment of relapsed/refractory B cell non-Hodgkin lymphoma.
Journal of translational medicinePrimary Solitary Rib Lymphoma on FDG PET/CT.
Clinical nuclear medicineCD20×CD3 Bispecific Antibodies in B-NHL: A Review of Translational Science, Pharmacokinetics, Pharmacodynamics, and Dose Strategy in Clinical Research.
Clinical and translational scienceWhen the mouth speaks first: oral Burkitt lymphoma unmasks HIV in a young male.
Oral oncologyPotential surrogate endpoint for B-cell hematologic malignancy: A systematic review and meta-analysis.
Scientific reportsAmyloidosis-Related Cardiomyopathy Revealing Waldenstrom Macroglobulinemia: A Case Report.
CureusSafety, pharmacokinetics, and efficacy of abexinostat, an novel histone deacetylase inhibitor, in Chinese patients with relapsed/refractory B cell non-Hodgkin lymphoma: a Phase 1 study.
BMC cancerEfficacy and safety of third-generation CD19-CAR T cells incorporating CD28 and TLR2 intracellular domains for B-cell malignancies with central nervous system involvement: results of a pivotal trial.
Journal of translational medicineImpact of SARS-CoV-2 infection on bispecific antibody treatment in patients with B-cell lymphoproliferative disorders.
Blood advancesHigh SRD5A3 expression is correlated with promotion of proliferation and inhibition of apoptosis in B-cell non-Hodgkin lymphoma and suggests a poor prognosis.
PloS oneEvaluation of the Antitumoral Effect of PI3K/AKT/mTOR Pathway Inhibition and Antioxidant Combination on Burkitt Lymphoma Cell Line.
Current cancer drug targetsHypogammaglobulinemia in Children Receiving Targeted Immunotherapies for B Lineage Malignancies: Practical Guidance for Assessment and Management.
Pediatric blood & cancer18F-FDG PET/CT for predicting prognosis of B-cell non-Hodgkin lymphoma patients treated with chimeric antigen receptor T cells: the value of pre-infusion and M1 image.
European journal of nuclear medicine and molecular imagingPush Forward Clinical Management of Hematological Toxicity due to Lenalidomide Overexposure: Model-Informed Precision Dosing for Chinese Population With Renal Insufficiency.
CPT: pharmacometrics & systems pharmacologyOutcomes of the transformation to diffuse large B-cell lymphoma in hodgkin lymphoma and indolent B-cell non-Hodgkin lymphoma: a population-based study.
Annals of hematologyOptimizing Outcomes in Childhood Mature B-cell Non-Hodgkin Lymphoma: Insights Into Staging, Risk Stratification, and Response Evaluation.
Journal of pediatric hematology/oncologyAberrant antioxidant responses in B-cell non-Hodgkin lymphoma.
British journal of haematologyComparative inhibitory effects of bepotastine and diphenhydramine on rituximab-induced infusion reactions.
International journal of hematologyChanges in sagittal spinopelvic alignment are associated with increased pain and impaired function in multiple myeloma patients.
European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research SocietyEEG as a predictive biomarker of neurotoxicity in anti-CD19 CAR T-cell therapy.
Journal of neurologyA Rare Case of Non-Hodgkin B-Cell Lymphoma Following Invasive Lobular Carcinoma of the Breast: A Case Report.
Current oncology (Toronto, Ont.)Coexistence of Acute Myeloid Leukemia and B-cell Non-Hodgkin Lymphoma Diagnosed on a Bone Marrow Trephine Biopsy.
CureusAn Autopsy Case of Bronchiolitis Obliterans Associated With Oral Lichen Planus and Non-Hodgkin Lymphoma.
CureusCD28-costimulated CD19 CAR-T cells for pediatric mature non-Hodgkin B-cell lymphoma.
Bone marrow transplantationCD20 xCD3 bispecific antibodies for large B cell lymphoma: latest updates from 2024 ASH annual meeting.
Journal of hematology & oncologyConcurrent papillary thyroid carcinoma and incidental cervical lymph node indolent B cell non-Hodgkin lymphoma: clinicopathological features, outcomes, and potential relationships.
World journal of surgical oncologyT-ICAHT: grading and prognostic impact of thrombocytopenia after CAR T-cell therapy.
BloodAn Autopsy for Persistent Coronavirus Disease 2019 Pneumonia during Follicular Lymphoma Treatment.
Internal medicine (Tokyo, Japan)Lenalidomide in combination with rituximab, dexamethasone, high-dose ARA-C and cisplatinum as salvage therapy in refractory or relapsed aggressive B-cell non-hodgkin-lymphoma - an open-label, multicentre phase I/II study (DSHNHL-R6).
Annals of hematologyPrognostic relevance of bone marrow immune cell fractions in newly diagnosed B-cell non-Hodgkin lymphoma patients.
Annals of medicinePPM1D Mutation as a Distinct Feature of Myeloid Neoplasms in B-Cell Non-Hodgkin Lymphoma Patients: A Retrospective Analysis.
CancersCytogenomic and Clinicopathologic Comparison of MYC-Positive and MYC-Negative High-Grade B-Cell Lymphoma With 11q Aberration in the Context of Other Aggressive Lymphomas With MYC Rearrangement.
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, IncCombination Treatment of Rituximab and Therapeutic Vaccines Affords Superior Tumor Suppression and Relapse Prevention for Non-Hodgkin Lymphoma.
Advanced materials (Deerfield Beach, Fla.)Evorpacept plus rituximab for the treatment of relapsed or refractory non-Hodgkin lymphoma: results from the phase I ASPEN-01 study.
HaematologicaPlasmablastic lymphoma mimicking primary ovarian, tubal or peritoneal cancer: a case report and literature review.
Discover oncologyPre-infusion 18 F-FDG PET/CT for Prognostic and Toxicity Prediction in B-cell Non-Hodgkin Lymphoma Patients Undergoing Chimeric Antigen Receptor T-cell Therapy.
Clinical nuclear medicineA viral infection prediction model for patients with r/r B-cell malignancies after CAR-T therapy: a retrospective analysis.
Frontiers in oncologyLILRB1-directed CAR-T cells for the treatment of hematological malignancies.
LeukemiaNon-relapse mortality with bispecific antibodies: A systematic review and meta-analysis in lymphoma and multiple myeloma.
Molecular therapy : the journal of the American Society of Gene TherapyEfficacy and safety of zanubrutinib combined with chimeric antigen receptor T-cell therapy targeting CD19 in refractory or relapsed diffuse large B cell lymphoma: A retrospective analysis.
Cancer treatment and research communicationsHigh-Dose Methotrexate Usage Without Drug-Level Monitoring in Advanced Pediatric Mature B-Cell Non-Hodgkin Lymphoma in a Resource-Limited Setting in Malawi.
JCO global oncologyMantle cell lymphoma: from pathogenesis to treatment for 2024 and beyond.
Panminerva medica[Chinese expert consensus on the application of flow cytometry in the diagnosis and detection of minimal residual disease in B-cell non-Hodgkin lymphoma (2025)].
Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhiCurrent Treatment Strategies and Supportive Care Practices in the Care of Children and Adolescents With Mature B-Cell Non-Hodgkin Lymphoma: A Survey of Children's Oncology Group Institutions.
Pediatric blood & cancerEnterocolitis associated with glofitamab-First report and clinicopathological findings in three cases.
British journal of haematologyAn evaluation of odronextamab for the treatment of multiple subtypes of relapsed/refractory B-cell non-Hodgkin lymphoma.
Expert opinion on biological therapyOdronextamab monotherapy in patients with relapsed/refractory diffuse large B cell lymphoma: primary efficacy and safety analysis in phase 2 ELM-2 trial.
Nature cancerBlastoid Mantle Cell Lymphoma Presenting as an Isolated Cecal Mass.
Journal of investigative medicine high impact case reportsFlow Cytometry for B-Cell Non-Hodgkin and Hodgkin Lymphomas.
CancersLymphoma-on-chip model reveals that lymph node stromal cells promote diffuse large B-cell lymphoma survival and migration.
Materials today. BioAllogeneic Stem Cell Transplantation in Participants With Hematologic Malignancies Following Pembrolizumab Therapy.
Transplantation and cellular therapyThe Genetic Influence of Programmed Death Ligand-1 (PD-L1) Single Nucleotide Polymorphisms on the Incidence of B-Cell Non-Hodgkin Lymphoma in a Cohort of Egyptians.
Asian Pacific journal of cancer prevention : APJCPComprehensive analysis of relapsed-refractory mature B-cell non-Hodgkin lymphoma in children and adolescents.
British journal of haematologyActinomycosis: Mimicking Malignancies in Multiple Anatomical Sites-A Three-Patient Case Series.
Medicina (Kaunas, Lithuania)A First-in-Human Phase I Study of LOXO-338, an Oral Selective Bcl-2 Inhibitor, in Patients With Advanced Hematologic Malignancies.
Clinical lymphoma, myeloma & leukemiaLate Adverse Events After Chimeric Antigen Receptor T-Cell Therapy for Patients With Aggressive B-Cell Non-Hodgkin Lymphoma.
JAMA network openThe Development and Application of Bispecific Antibodies in B-Cell Non-Hodgkin Lymphoma.
Journal of personalized medicinePrognostic Value of Peripheral Blood Lymphocyte Subsets in Children and Adolescents With High-Grade Mature B-Cell Non-Hodgkin Lymphoma: A Real-World Outcomes Study.
Pediatric blood & cancerClinical and molecular characteristics of paediatric mature B-cell acute lymphocytic leukaemia and non-Hodgkin lymphoma with bone marrow involvement: A joint study between the CCCG leukaemia and lymphoma groups.
British journal of haematologyFCRL1 and BAFF mRNA Expression as Novel Diagnostic and Prognostic Biomarkers in Diffuse Large B-Cell Lymphoma: Expression Signatures Predict R-CHOP Therapy Response and Survival.
International journal of molecular sciencesImpact of Filgrastim on Mortality During Induction Chemotherapy in Childhood B-Cell Non-Hodgkin Lymphoma.
CureusThe pathogenesis of B-cell non-hodgkin lymphoma associated with HBV (hepatitis B virus) infection is regulated by c-Myc/PD-L1 signaling pathway.
Global medical geneticsDirect-Acting Antivirals Induce Lymphoproliferative Disease Response in HCV-Infected Patients With Indolent B-Cell Non-Hodgkin's Lymphoma: A Prospective Observational Study.
Hematological oncologyExclusion of People Living with HIV in Aggressive B-Cell Non-Hodgkin Lymphoma Studies: A Cross-Sectional Analysis of Clinical Trials from 2014 to 2024.
Cancer investigationUse of rituximab in mature, high-grade and advanced-stage pediatric B-lineage non-Hodgkin lymphomas: a systematic review, meta-analysis and the Brazilian reality.
Frontiers in pediatricsAdvances in the Pathogenesis, Diagnosis, Treatment, and Prognosis of Marginal Zone Lymphoma.
Current treatment options in oncologyLong-term survival and clinical implications of allogeneic stem cell transplantation in relapse/refractory lymphoma: A 20-year Singapore experience.
Annals of the Academy of Medicine, SingaporeEvolutionary trajectories of immune escape across cancers.
bioRxiv : the preprint server for biologyUpregulation of CD19 by low-dose chidamide promotes CAR T cells functionality in B-cell non-Hodgkin lymphoma.
Discover oncologyPrognostic risk factors of pneumonia associated with COVID-19 in patients with lymphoma.
Frontiers in oncologyHigher Mortality Risk From Ovarian Carcinomas, Small Bowel Neoplasms, and B-Cell and Mucosa-Associated Lymphoid Tissue Lymphomas in Sjögren Syndrome Patients.
Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseasesEnhancing Diagnostic Precision: Intracardiac Echocardiography-Guided Endomyocardial Biopsy for Complex Right Atrial Mass.
JACC. Case reportsA phase 1 trial of prizloncabtagene autoleucel, a CD19/CD20 CAR T-cell therapy for relapsed/refractory B-cell non-Hodgkin lymphoma.
BloodAssociações
Organizações que acompanham esta doença — pra ter apoio e orientação
Ainda não temos associações cadastradas para Linfoma não-Hodgkin de células B.
É de uma associação que acompanha esta doença? Fale com a gente →
Doença com base genética
Um médico geneticista pode ajudar no diagnóstico de Linfoma não-Hodgkin de células B e no aconselhamento genético da família.
Doenças relacionadas
Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico
Perguntas frequentes
O que as famílias mais perguntam sobre esta doença — cada resposta com a fonte de onde saiu
É a categoria mais frequente de linfoma não-Hodgkin descrita na literatura médica. Abrange subtipos conhecidos, incluindo o linfoma folicular e o linfoma difuso de grandes células B.
Referências
Fontes citadas no texto, publicações do grafo e bases de dados usadas neste verbete
10 publicações do grafo RarasNet (PubMed) · 6 bases de dados. Títulos, periódicos e PMIDs vêm direto da fonte, sem intermediação de IA.
Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.
Citar este verbete
Raras. (s.d.). Linfoma não-Hodgkin de células B. Em Raras — Enciclopédia de Doenças Raras do Brasil. https://raras.org/doenca/linfoma-nao-hodgkin-de-celulas-b
Formato APA. Conteúdo sob CC BY 4.0 — reuso livre com atribuição.
Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar
Linfoma não-Hodgkin de células B
📋 Origem dos dados
Esta página agrega dados de fontes públicas e oficiais. Dados sobre cobertura no SUS (PCDT, CEAF) são verificados ativamente por agente proativo (ver badge no infobox). Demais dados têm atribuição de fonte + data da última sincronização — clique para abrir o original.
- Doença rara (ontologia)
- fonte: Orphanet
- Identificador unificado
- fonte: MONDO
- NIH/GARD
- fonte: GARD (NIH)
- Dado público estruturado
- fonte: Wikidata
- Medicamentos aprovados FDA
- fonte: FDA OpenFDA
- Ensaios clínicos
- fonte: ClinicalTrials.gov
